Abstract 18979: Identification of a Novel Small Molecule That Regulates Lipid Metabolism by Enhancing ABCA1 Expression

Xiao Wang,Yongzhen Li,Chao Liu,Ni Li,Jun Luo,Xuan Zuo,Xu Yang,Shuyi Si

IF: 37.8

2017-01-01

Circulation

Abstract:Introduction and objectives: A large number of epidemiological studies have found that serum High-density lipoprotein cholesterol (HDL-C) level is inversely associated with the risk of atherosclero...

What problem does this paper attempt to address?

Abstract 18982: E3317 Promotes Cholesterol Efflux in Macrophage Cells Via Enhancing ABCA1 Expression

Xu Yang,Xiao Wang,Ni Li,Chao Liu,Xuan Zuo,Jun Luo,Shuyi Si

IF: 37.8

2017-01-01

Circulation

Abstract:Introduction: Reverse cholesterol transport (RCT) is a process which plays an important role in cholesterol, lipid and glucose metabolism. Regulating the activities of key transporters and receptor...
Abstract 15297: Discovery and Preclinical Optimization of Selective ABCA1 Inducers as Multifunctional Therapeutic Candidates

Cutler Lewandowski,Md. Wasim Khan,Manel Ben Aissa,Brian Layden,Gregory Thatcher

DOI: https://doi.org/10.1161/circ.142.suppl_3.15297

IF: 37.8

2020-11-17

Circulation

Abstract:Introduction: Reduced expression of cholesterol transporter ABCA1 is critical in pathogenesis of type 2 diabetes (T2D) and related conditions, such as cardiovascular disease (CVD) and Alzheimer’s disease (AD). Thus, increasing ABCA1 represents a novel therapeutic strategy for these conditions. However, prior drug development efforts have achieved limited success at increasing ABCA1 (controlled by liver X receptor [LXR] β) while avoiding unwanted liver triglyceride production (through LXRα via transcription factor SREBP1c). Hypothesis: We hypothesized that phenotypic screening for selective ABCA1 inducers followed by medicinal chemistry optimization would bypass the isoform selectivity issues encountered in traditional target-based drug discovery and enable development of lead therapeutic candidates with preclinical efficacy and safety. Methods/Results: We screened 20k compounds for ABCA1 and SREBP1c-linked luciferase activity, followed by qPCR to validate and prioritize selective ABCA1-inducing hits. We synthesized ~70 structural analogs of the best hit, achieving substantial EC 50 (4.5 μM to 270 nM) and E max (3.5-fold to 6.0-fold vs. vehicle) improvements in ABCA1 luciferase assay while maintaining selectivity against SREBP1c. Direct binding assays confirmed selectivity for LXRβ vs. LXRα, corroborating cell-based data. Lead compounds enhanced cellular cholesterol efflux, reduced inflammation in vitro , and attenuated high-fat diet (HFD) induced weight gain, insulin resistance, and inflammation in mice. Metabolomics analysis revealed that our lead compound corrected HFD-induced perturbations in liver glucose and fatty acid synthesis. Finally, side effects associated with published LXR agonists - liver steatosis and neutropenia - were not observed with our compound. Conclusions: We established a platform to develop selective ABCA1 inducers as drug candidates. Via this platform, we identified a safe and efficacious lead compound for T2D. Our study also represents the first report of an LXR agonist characterized by metabolomics - a powerful tool to complement biochemical readouts. Continued optimization to improve pharmacokinetic parameters, plus evaluation in CVD and AD models, is ongoing.

cardiac & cardiovascular systems,peripheral vascular disease
Synthesis and Identification of New Flavonoids Targeting Liver X Receptor Β Involved Pathway As Potential Facilitators of Aβ Clearance with Reduced Lipid Accumulation.

Yun Hu,Yaqi Yang,Yanjun Yu,Gesi Wen,Nana Shang,Wei Zhuang,Dihan Lu,Binhua Zhou,Baoxia Liang,Xin Yue,Feng Li,Jun Du,Xianzhang Bu

DOI: https://doi.org/10.1021/jm301913k

IF: 8.039

2013-01-01

Journal of Medicinal Chemistry

Abstract:Alzheimer's disease (AD) is associated with impaired Aβ degradation in the brain. Enhancing the process of Aβ clearance is an attractive potential AD therapy. Treatment with LXR agonists may reduce Aβ levels in vivo. However, the clinical potential of many LXR agonists is limited because of their nonselective actions on LXRα/β, which lead to undesired hepatic lipogenesis via LXRα-dependent pathways. In this study, ABCA1 up-regulators were identified from a series of flavonoids and were found to preferentially activate LXRβ and up-regulate expression of ABCA1 and apoE in different cell lines. Further investigations confirmed that these compounds facilitate intracellular Aβ clearance in Aβ-loaded BV2 cells. Administration of compound 19 reduced total brain Aβ and plaque burden in APP/PS1 double transgenic mice, associated with elevated ABCA1 and apoE expression. Compared with the nonselective LXR agonists, the active compounds reported here induced less accumulation of undesired lipids and triglycerides in HepG2 cells.
Identification of Novel Human High-Density Lipoprotein Receptor Up-regulators Using a Cell-Based High-Throughput Screening Assay

Yuan Yang,Zhongbing Zhang,Wei Jiang,Lei Gao,Guiyu Zhao,Zhihui Zheng,Min Wang,Shuyi Si,Bin Hong

DOI: https://doi.org/10.1177/1087057106297568

IF: 3.341

2007-03-01

SLAS DISCOVERY

Abstract:Scavenger receptor class B type I (SR-BI) is the high-affinity high-density lipoprotein (HDL) receptor, and CLA-1 is the human homologue of the murine SR-BI. CLA-1/SR-BI receptor has been suggested as a new preventative and/or therapeutic target for atherosclerosis due to its pivotal role in overall HDL cholesterol (HDL-C) metabolism and its antiatherogenic activity in vivo. To search for active compounds that can increase CLA-1 transcription, a novel cell-based assay was developed for application in high-throughput screening (HTS). Human hepatoma HepG2 cells were transfected with a CLA-1-promoter-luciferase reporter gene construct, and the stable transfected cell line was selected and named CLAp-LUC HepG2. With rosiglitazone as a positive control, this stable cell line was used to establish a specific CLA-1 gene expression assay in a 96-well microplate format. The evaluating parameter Z' value of 0.64 showed that this cell-based HTS assay was robust and reliable. Screening of 6000 microbial secondary metabolite crude extracts identified 8 positive strains. Between 2 identified CLA-1 up-regulators produced by actinomycete strain 04-4776, 4776B may stimulate not only the expression of CLA-1 on the transcriptional and translational levels but also the activity of CLA-1 to uptake the HDL-C in HepG2 cells. The active compounds originated from this HTS assay may be developed to drug candidates or lead compounds for new antiatherosclerosis agents.

biochemical research methods,biotechnology & applied microbiology,chemistry, analytical
Targeted inhibition of ATP-binding cassette transporter A1 protein degradation promotes reverse cholesterol transport and reduces atherosclerosis in mice (832.15)

linzhang huang,haibo zhu

DOI: https://doi.org/10.1096/fasebj.28.1_supplement.832.15

2014-01-01

The FASEB Journal

Abstract:Objective ATP‐Bing Cassette Transporter A1 (ABCA1) is a key protein in the rate‐limiting step of reverse cholesterol transport, which maintains plasma HDL levels. Transcriptional regulating ABCA1 promotes HDL generation and RCT is well established, however, little is known about the posttranspcriptional inhibition of ABCA1 degradation on macrophage RCT and atherosclerosis. We therefore investigate whether suppressing ABCA1 degradation would promote RCT and reduce atherosclerosis. Methods and results Pulse‐chase analysis revealed that a small molecular (IMM‐H007) significantly inhibits ABCA1 degradation and facilitates its cell‐surface localization in THP‐1 macrophages. In vitro tests described that IMM‐H007 promote cholesterol efflux via ABCA1‐mediated pathway. Animals fed a western diet containing 1.25% cholesterol with IMM‐H007 treatment showed an increase in circulating HDL levels and enhanced RCT to the plasma, liver, and feces. Additional, elevated hepatic ABCA1 expression and functional HDL were also observed in mice after IMM‐H007 administration. Furthermore, suppressing ABCA1 degradation gave rise to the reduction of plaque size, lipid content and increase markers of plaque stability in apoE‐/‐ mice. Conclusion Our findings reveal that raising HDL levels by inhibiting ABCA1 protein degradation enhances reverse cholesterol transport and decreases plaque formation, suggesting that it is a promising HDL therapeutic strategy to protect against atherosclerotic. IMM‐H007 could be a leading compound for development of drugs for raising HDL quantity and function.
Small molecule inducers of ABCA1 and apoE that act through indirect activation of the LXR pathway

Jianjia Fan,Rui Qi Zhao,Cameron Parro,Wenchen Zhao,Hsien-Ya Chou,Jerome Robert,Tarek Z Deeb,Carina Raynoschek,Samantha Barichievy,Ola Engkvist,Marcello Maresca,Ryan Hicks,Johan Meuller,Stephen J Moss,Nicholas J Brandon,Michael W Wood,Iva Kulic,Cheryl L Wellington

DOI: https://doi.org/10.1194/jlr.M081851

Abstract:apoE is the primary lipid carrier within the CNS and the strongest genetic risk factor for late onset Alzheimer's disease (AD). apoE is primarily lipidated via ABCA1, and both are under transcriptional regulation by the nuclear liver X receptor (LXR). Considerable evidence from genetic (using ABCA1 overexpression) and pharmacological (using synthetic LXR agonists) studies in AD mouse models suggests that increased levels of lipidated apoE can improve cognitive performance and, in some strains, can reduce amyloid burden. However, direct synthetic LXR ligands have hepatotoxic side effects that limit their clinical use. Here, we describe a set of small molecules, previously annotated as antagonists of the purinergic receptor, P2X7, which enhance ABCA1 expression and activity as well as apoE secretion, and are not direct LXR ligands. Furthermore, P2X7 is not required for these molecules to induce ABCA1 upregulation and apoE secretion, demonstrating that the ABCA1 and apoE effects are mechanistically independent of P2X7 inhibition. Hence, we have identified novel dual activity compounds that upregulate ABCA1 across multiple CNS cell types, including human astrocytes, pericytes, and microglia, through an indirect LXR mechanism and that also independently inhibit P2X7 receptor activity.
Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice

LinZhang Huang,BaoYan Fan,Ang Ma,Philip W Shaul,HaiBo Zhu

DOI: https://doi.org/10.1194/jlr.M054742

IF: 6.676

2015-01-01

Journal of Lipid Research

Abstract:ABCA1 plays a key role in the initial lipidation of apoA-I, which generates circulating HDL cholesterol. Whereas it is known that the transcriptional upregulation of ABCA1 promotes HDL formation and reverse cholesterol transport (RCT), it is not known how the inhibition of ABCA1 protein degradation impacts HDL function. Employing the small molecule triacetyl-3-hydroxyphenyladenosine (IMM-H007), we determined how the attenuation of ABCA1 protein degradation affects HDL cholesterol efflux capacity, RCT, and atherosclerotic lesion formation. Pulse-chase analysis revealed that IMM-H007 inhibits ABCA1 degradation and facilitates its cell-surface localization in macrophages, and additional studies in macrophages showed that IMM-H007 thereby promotes cholesterol efflux. IMM-H007 treatment of Paigen diet-fed mice caused an increase in circulating HDL level, it increased the cholesterol efflux capacity of HDL, and it enhanced in vivo RCT from macrophages to the plasma, liver, and feces. Furthermore, ABCA1 degradation suppression by IMM-H007 reduced atherosclerotic plaque formation in apoE(-/-) mice. Thus, via effects on both ABCA1-expressing cells and circulating HDL function, the inhibition of ABCA1 protein degradation by IMM-H007 promotes HDL cholesterol efflux capacity and RCT and attenuates atherogenesis. IMM-H007 potentially represents a lead compound for the development of agents to augment HDL function.
Abstract 506: the Role of Apolipoprotein A-V in Chylomicron Metabolism

Xenia Davis,Chih‐Wei Ko,Sarah Fourman,Qing Yang,Min Liu,Patrick Tso

2019-01-01

Abstract:Introduction: Cardiovascular disease, diabetes and obesity are major clinical problems, and elevated plasma triglyceride (TG) levels are a risk factor for these disorders. Discovered in 2001, apoli...
Lipid reducing activity of novel cholic acid (CA) analogs: Design, synthesis and preliminary mechanism study.

Guoshun Luo,Zhouyang Qian,Rongmao Qiu,Qidong You,Hua Xiang

DOI: https://doi.org/10.1016/j.bioorg.2018.07.002

IF: 5.307

2018-01-01

Bioorganic Chemistry

Abstract:Bile acids, initially discovered as endogenous ligands of farnesoid X receptor (FXR), play a central role in the regulation of triglyceride and cholesterol metabolism and have recently emerged as a privileged structure for interacting with nuclear receptors relevant to a large array of metabolic processes. In this paper, phenoxy containing cholic acid derivatives with excellent drug-likeness have been designed, synthesized, and assayed as agents against cholesterol accumulation in Raw264.7 macrophages. The most active compound 14b reduced total cholesterol accumulation in Raw264.7 cells up to 30.5% at non-toxic 10 μM and dosage-dependently attenuated oxLDL-induced foam cell formation. Western blotting and qPCR results demonstrate that 14b reduced both cholesterol and lipid in Raw264.7 cells through (1) increasing the expression of cholesterol transporters ABCA1 and ABCG1, (2) accelerating ApoA1-mediated cholesterol efflux. Through a cell-based luciferase reporter assay and molecular docking analysis, LXR was identified as the potential target for 14b. Interestingly, unlike conventional LXR agonist, 14b did not increase lipogenesis gene SREBP-1c expression. Overall, these diverse properties disclosed herein highlight the potential of 14b as a promising lead for further development of multifunctional agents in the therapy of cardiovascular disease.
Native LDL Upregulation of ATP-Binding Cassette Transporter-1 in Human Vascular Endothelial Cells

HL Liao,T Langmann,G Schmitz,Y Zhu

DOI: https://doi.org/10.1161/hq1201.101772

2002-01-01

Arteriosclerosis Thrombosis and Vascular Biology

Abstract:ATP-binding cassette transporter-1 (ABCA1) mediates the lipid efflux from cells to apolipoproteins. In studying the gene expression and regulation of ABCA1 in human vascular endothelial cells (ECs), we found that native low density lipoprotein (LDL) elevates ABCA1 in both protein and mRNA levels in a time- and dose-dependent fashion. Transfection of full-length human ABCA1 in ECs lowers cellular cholesterol content and increases apolipoprotein (apo) A-I-mediated cholesterol efflux. Transfection of the ABCA1 promoter-luciferase reporter results in a 2-fold induction after LDL exposure. The responsive element was mapped within - 116 to -54 of the promoter region with use of promoter deletion constructs, as reported in other cells. A mutation of the DR4 site greatly diminished the LDL effect. Results showing that LDL increases the liver X receptor responsive element (LXRE)-driven luciferase activity demonstrate the effect of LDL on LXR activation. Furthermore, ligands of the retinoid X receptor and LXR activate ABCA1 in ECs at levels of both promoter activation and mRNA induction. Therefore, ABCA1 is expressed in vascular ECs and is transcriptionally upregulated by LDL. Overexpression of ABCA1 in these cells prevents overloading of cholesterol by increasing the efflux of cholesterol. Thus, ABCA1 plays an important role in the homeostasis of cholesterol in the vascular endothelium.
Abstract 1453: LXR-623, a Novel Liver X Receptor Modulator, Displays Neutral Lipid Effects in Cholesteryl Ester Transfer Protein-expressing Species and Inhibits Atherosclerotic Lesion Progression in Low Density Lipoprotein Receptor Knockout Mice

Ponnal Nambi,Michael Basso,Liang Chen,Qiang-Yuan Liu,Anita R Halpern,Valérie Clerin,Christine Resmini,James C. Keith,Irene Feingold,Robert J. Steffan,Jay Wrobel,Elaine Quinet

IF: 37.8

2007-01-01

Circulation

Abstract:LXRα and LXRα are ligand-activated transcription factors involved in the upregulation of genes involved in reverse cholesterol transport (RCT), a process involved in cholesterol homeostasis. Unfort...
Inhibition of Soluble Epoxide Hydrolase in Mice Promotes Reverse Cholesterol Transport and Regression of Atherosclerosis

Li Shen,Hongchun Peng,Ran Peng,Qingsong Fan,Shuiping Zhao,Danyan Xu,Christophe Morisseau,Nipavan Chiamvimonvat,Bruce D. Hammock

DOI: https://doi.org/10.1016/j.atherosclerosis.2015.02.014

IF: 5.3

2015-01-01

Atherosclerosis

Abstract:Adipose tissue is the body largest free cholesterol reservoir and abundantly expresses ATP binding cassette transporter A1 (ABCA1), which maintains plasma high-density lipoprotein (HDL) levels. HDLs have a protective role in atherosclerosis by mediating reverse cholesterol transport (RCT). Soluble epoxide hydrolase (sEH) is a cytosolic enzyme whose inhibition has various beneficial effects on cardiovascular disease. The sEH is highly expressed in adipocytes, and it converts epoxyeicosatrienoic acids (EETs) into less bioactive dihydroxyeicosatrienoic acids. We previously showed that increasing EETs levels with a sEH inhibitor (sEHI) (t-AUCB) resulted in elevated ABCA1 expression and promoted ABCA1-mediated cholesterol efflux from 3T3-L1 adipocytes. The present study investigates the impacts of t-AUCB in mice deficient for the low density lipoprotein (LDL) receptor (Ldlr(-/-) mice) with established atherosclerotic plaques. The sEH inhibitor delivered in vivo for 4 weeks decreased the activity of sEH in adipose tissue, enhanced ABCA1 expression and cholesterol efflux from adipose depots, and consequently increased HDL levels. Furthermore, t-AUCB enhanced RCT to the plasma, liver, bile and feces. It also showed the reduction of plasma LDL-C levels. Consistently, t-AUCB-treated mice showed reductions in the size of atherosclerotic plaques. These studies establish that raising adipose ABCA1 expression, cholesterol efflux, and plasma HDL levels with t-AUCB treatment promotes RCT, decreasing LDL-C and atherosclerosis regression, suggesting that sEH inhibition may be a promising strategy to treat atherosclerotic vascular disease. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
ABCG1--a potential therapeutic target for atherosclerosis.

Zhan-ling Ni,Shui-ping Zhao,Zhihong Wu

DOI: https://doi.org/10.1016/j.mehy.2006.06.042

IF: 4.7

2007-01-01

Medical Hypotheses

Abstract:Cholesterol efflux from macrophage foam cells, the initial step of reverse cholesterol transport, is assumed to be the most relevant step with respect to atherosclerosis. As one of the ATP-binding cassette transporter (ABC) family members, ABCG1 plays a critical role in the process of cholesterol efflux. It has been recently identified to export cellular cholesterol to large HDL particles. For mature HDL constitutes the bulk of the plasma HDL, ABCG1 is responsible for the majority of the cholesterol efflux from macrophage foam cells to serum. Overexpression of ABCG1 improves HDL function through stimulating cholesterol export. Therefore, it could be hypothesized that ABCG1 would be a new target for the treatment of atherosclerosis.
The Effect of T0901317 on ATP-binding Cassette Transporter A1 and Niemann-Pick Type C1 in Apoe-/- Mice.

Xiao-yan Dai,Xiang Ou,Xin-rui Hao,Dong-li Cao,Ya-ling Tang,Yan-wei Hu,Xiao-xu Li,Chao-ke Tang

DOI: https://doi.org/10.1097/fjc.0b013e31816a5be3

IF: 3.271

2008-01-01

Journal of Cardiovascular Pharmacology

Abstract:Although a range of studies indicated Liver X receptor (LXR) activation inhibited the development of atherosclerosis in animal models, the mechanism of this effect for LXR agonists has not been fully understood. A recent study has suggested LXR activators increased the amount of free cholesterol in the plasma membrane of human macrophages by inducing Niemann-Pick type C1 (NPC1) gene expression. Therefore, we hypothesize that LXRs may also promote NPC1 expression in vivo. Here we investigated the effect of a synthetic LXR agonist T0901317 on ATP-binding cassette transporter A1 (ABCA1) and NPC1 in apolipoprotein E knockout (apoE-/-) mice. Male apoE-/- mice were randomized into four groups: baseline group (n = 10), vehicle group (n = 14), prevention group (n = 14), and treatment group (n = 14). En face analysis and Oil red O staining were used to examine the aortic atherosclerotic lesions. Macrophage content of aortic root atherosclerotic lesions and cholesterol efflux form peritoneal macrophages were measured. Gene and protein expression was analyzed by real-time quantitative polymerase chain reaction and Western blotting, respectively. T0901317 treatment reduced aortic atherosclerotic lesion area by 64.2% in prevention group (P < 0.001) and 58.3% in treatment group (P < 0.001) and resulted in a reduction in macrophage content. Plasma triglyceride, total cholesterol, high-density lipoprotein cholesterol, and apoA-I concentrations were markedly increased in T0901317-treated groups. T0901317 also promoted ABCA1 and NPC1 gene and protein levels in the aorta, liver, and small intestine of apoE-/- mice and significantly increased cholesterol efflux from peritoneal macrophages. T0901317 upregulates ABCA1 and NPC1. This study gives us a new insight into the mechanism for antiatherogenic effect of LXR synthetic agonists.
Nonlipogenic ABCA1 Inducers (NLAI) for Alzheimer's Disease Validated in a Mouse Model Expressing Human APOE3/APOE4

Ganga Reddy Velma,Megan S. Laham,Cutler Lewandowski,Ana C. Valencia-Olvera,Deebika Balu,Annabelle Moore,Martha Ackerman-Berrier,Pavel Rychetsky,Christopher Penton,Soumya Reddy Musku,Anandhan Annadurai,Maha Ibrahim Sulaiman,Nina Ma,Gregory R J Thatcher

DOI: https://doi.org/10.1021/acs.jmedchem.4c00733

IF: 8.039

2024-08-30

Journal of Medicinal Chemistry

Abstract:Therapeutics enhancing apolipoprotein (APOE) positive function are a priority, because APOE4 is the major genetic risk factor for Alzheimer's disease (AD). The function of APOE, the key constituent of lipoprotein particles that transport cholesterol and lipids in the brain, is dependent on lipidation by ABCA1, a cell-membrane cholesterol transporter. ABCA1 transcription is regulated by liver X receptors (LXR): agonists have been shown to increase ABCA1, often accompanied by unwanted lipogenesis...

chemistry, medicinal
Abstract 225: Regulation Of Plasma Lipoproteins And Atherosclerosis By Microrna-541-3p And Transcription Factors Znf101 And Casz1

Abulaish Ansari,Pradeep Kumar Yada,Liye Zhou,Laraib Ijaz,Amanda christiano,Sameer Ahmad,Antoine Rimbert,M M Hussain

DOI: https://doi.org/10.1161/atvb.43.suppl_1.225

2023-05-01

Abstract:High apoB-containing low-density lipoproteins (LDL) and low apoA1-containing high-density lipoproteins (HDL) are associated with atherosclerotic cardiovascular disease. MicroRNAs (miRs) are small non-coding RNAs that modulate multiple pathways. We screened a miR library in human liver cells and identified miR-541-3p that decreases apoB and increases apoA1 by inducing the degradation of mRNAs of two different transcription factors, Znf101 and Casz1. Molecular and physiological studies revealed that Znf101 enhances apoB expression and that Casz1 represses apoA1 expression. Thus, miR-541-3p differentially regulates apoB and apoA1 expression by reducing the expression of an enhancer and a repressor. Moreover, the hepatic knockdown of orthologous genes in mice reduced plasma lipids and atherosclerosis. Mechanistic studies revealed that lower hepatic lipoprotein production and increased HDL cholesterol efflux capacity might contribute to reductions in atherosclerosis. In addition, these livers showed reduced expression of genes involved in lipogenesis. Furthermore, knockdown of these genes and overexpression of miR-541-3p in human liver cells reduced lipogenesis. Thus, in addition, to apolipoprotein/lipoprotein production, miR-541-3p also regulates hepatic lipid synthesis. By screening human genetic datasets, we found that genetic variants in MIR541 , ZNF101 and CASZ1 loci are significantly associated with plasma lipid and lipoprotein levels. This study suggests miR-541-3p, Znf101 and Casz1 as potential therapeutic agents/targets to reduce plasma lipids, lipoproteins and atherosclerosis without causing steatosis.

peripheral vascular disease,hematology
Identification of A Novel Partial Agonist of Liver X Receptor Alpha (lxr Alpha) Via Screening

Ni Li,Xiao Wang,Jing Zhang,Chang Liu,Yongzhen Li,Tingting Feng,Yanni Xu,Shuyi Si

DOI: https://doi.org/10.1016/j.bcp.2014.09.017

IF: 6.1

2014-01-01

Biochemical Pharmacology

Abstract:Liver X receptor a (LXR alpha) plays an important role in the cholesterol metabolism process, and LXRa activation can reduce atherosclerosis. In the present study, using an LXR alpha-GAL4 luciferase reporter screening, we discovered IMB-170, a structural analog of quinazolinone, which showed potent LXRa agonistic activity. IMB-170 significantly activated LXRa, with an EC50 value of 0.27 mu M. Interestingly, IMB-170 not only increased the expression of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1), which are related to the reverse cholesterol transport (RCT) process, but also influenced the expression levels of other genes involved in the cholesterol metabolism pathway in many cell lines. Moreover, IMB-170 significantly reduced cellular lipid accumulation and increased cholesterol efflux from RAW264.7 and THP-1 macrophages. Interestingly, compared with T0901317, IMB-170 only slightly increased protein expression levels of lipogenesis-related genes in HepG2 cells, indicating that IMB-170 may have a lower lipogenesis Side effect in vivo. These results suggest that IMB-170 showed the selective agonistic activity for LXRa. Moreover, compared with full LXR-agonists, IMB-170 possesses a differential ability to recruit coregulators. This suggests that IMB-170 has distinct interactions with the active sites in the LXRa ligand-binding domain. In summary, IMB-170 is a novel partial LXRa agonist without the classical lipogenesis side effects, which could be used as a potential anti-atherosclerotic leading compound in the future. (C) 2014 Elsevier Inc. All rights reserved.
Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway

Xin Li,Xueling Hu,Tengfei Pan,Lei Dong,Lili Ding,Zhenzhong Wang,Rui Song,Xiuzhu Wang,Ning Wang,Yan Zhang,Jinhui Wang,Baofeng Yang

DOI: https://doi.org/10.1016/j.biopha.2020.110802

2021-01-01

Abstract:Hyperlipidaemia is one of the major risk factors for atherosclerosis, coronary heart disease, stroke and diabetes. In the present study, we synthesized a new anthraquinone compound, 1,8-dihydroxy-3-succinic acid monoethyl ester-6-methylanthraquinone, and named it Kanglexin (KLX). The aim of this study was to evaluate whether KLX has a lipid-lowering effect and to explore the potential molecular mechanism. In this study, Sprague-Dawley rats were fed a high fat diet (HFD) for 5 weeks to establish a hyperlipidaemia model; then, the rats were orally administered KLX (20, 40, and 80 mg kg−1·d−1) or atorvastatin calcium (AT, 10 mg kg−1·d−1) once a day for 2 weeks. KLX had prominent effects on reducing blood lipids, hepatic lipid accumulation, body weight and the ratio of liver weight/body weight. Furthermore, KLXdramatically reduced the total cholesterol (TC) and triglyceride (TG) levels and lipid accumulation in a HepG2 cell model of dyslipidaemia induced by 1 mmol/L oleic acid (OA). KLX may decrease lipid levels by phosphorylating adenosine monophosphate-activated protein kinase (AMPK) and the downstream sterol regulatory element binding protein 2 (SREBP-2)/proprotein convertase subtilisin/kexin type 9 (PCSK9)/low-density lipoprotein receptor (LDLR) signalling pathway in the HFD rats and OA-treated HepG2 cells. The effects of KLX on the AMPK/SREBP-2/PCSK9/LDLR signalling pathway were abolished when AMPK was inhibited by compound C (a specific AMPK inhibitor) in HepG2 cells. In summary, KLX has an efficient lipid-lowering effect mediated by activation of the AMPK/SREBP-2/PCSK9/LDLR signalling pathway. Our findings may provide new insight into and evidence for the discovery of a new lipid-lowering drug for the prevention and treatment of hyperlipidaemia, fatty liver, and cardiovascular disease in the clinic.

pharmacology & pharmacy,medicine, research & experimental
Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial

Jiang Wang,Jing Zhao,Cong Yan,Cong Xi,Chenglin Wu,Jingxiang Zhao,Fengwei Li,Yanhua Ding,Rui Zhang,Shankang Qi,Xingjun Li,Chao Liu,Wanting Hou,Hong Chen,Yiping Wang,Dalei Wu,Kaixian Chen,Hualiang Jiang,He Huang,Hong Liu

DOI: https://doi.org/10.1016/j.cmet.2022.03.006

IF: 29

2022-04-01

Cell Metabolism

Abstract:Developing non-statin-based small compounds to battle the global epidemic of hyperlipidemia remains challenging. Here, we report the discovery of DC371739, an indole-containing tetrahydroisoquinoline compound with promising lipid-lowering effects, both in vitro and in vivo, and with good tolerability in a Phase I clinical trial (NCT04927221). DC371739 significantly reduced the plasma levels of total cholesterol, low-density lipoprotein cholesterol, and triglycerides simultaneously in several animal models and showed preliminary positive results in the Phase I trial. Mechanistically, DC371739 acts in a distinct manner from other known lipid-lowering reagents. We show that it physically binds HNF-1α, impeding the transcription of both PCSK9 and ANGPTL3, two genes that are known to contribute to hypercholesterolemia and dyslipidemia. Moreover, the distinct mechanism of action of DC371739 allows its combination with atorvastatin treatment to additively improve dyslipidemia, while providing a potential alternative therapeutic strategy for individuals with statin intolerance.

cell biology,endocrinology & metabolism
Glucagon-like peptide-1 contributes to increases ABCA1 expression by downregulating miR-758 to regulate cholesterol homeostasis.

Yue Yao,Qiang Li,Ping Gao,Wei Wang,Lili Chen,Jinchao Zhang,Yi Xu

DOI: https://doi.org/10.1016/j.bbrc.2018.02.126

IF: 3.1

2018-01-01

Biochemical and Biophysical Research Communications

Abstract:Abnormal regulation of lipid metabolism is associated with type 2 diabetes mellitus (T2DM). GLP-1 as a new treatment for T2DM, has unique effects in modulating cholesterol homeostasis. However, the mechanism of this effect is largely missing. The aim of this study was to determine the effects of GLP-1 on cholesterol-induced lipotoxicity in hepatocytes and examine the underlying mechanisms. The cell viability was determined, and caspase-3 was used to detect the effects of GLP-1 on cholesterol-induced apoptosis. The alterations of miR-758 and ATP-binding cassette transporter A1 (ABCA1) resulting from cholesterol incubation or GLP-1 were detected by qRT-PCR and Western blot assays. Overexpression of miR-758 abrogated the GLP-1-mediated ABCA1 expression, and conversely, down-regulation of miR-758 aggravated GLP-1's action and revealed significant promotion effects. BODIPY-Cholesterol efflux assay revealed that treatment with miR-758 inhibitor significantly enhanced ABCA1-dependent cholesterol efflux, resulting in reduced total cholesterol. Furthermore, Oil red O staining and cholesterol measurement were used to detect lipid accumulation. As a result, cholesterol significantly attenuated cell viability, promoted cell apoptosis, and facilitated lipid accumulation, and these effects were reversed by GLP-1. This study provides evidence that, in HepG2 cells, GLP-1 may affect cholesterol homeostasis by regulating the expression of miR-758 and ABCA1. These data can inform the development of biomarkers for miR-758, and potentially other drugs, on the key pathways of lipid metabolism.

Abstract 18979: Identification of a Novel Small Molecule That Regulates Lipid Metabolism by Enhancing ABCA1 Expression

Abstract 18982: E3317 Promotes Cholesterol Efflux in Macrophage Cells Via Enhancing ABCA1 Expression

Abstract 15297: Discovery and Preclinical Optimization of Selective ABCA1 Inducers as Multifunctional Therapeutic Candidates

Synthesis and Identification of New Flavonoids Targeting Liver X Receptor Β Involved Pathway As Potential Facilitators of Aβ Clearance with Reduced Lipid Accumulation.

Identification of Novel Human High-Density Lipoprotein Receptor Up-regulators Using a Cell-Based High-Throughput Screening Assay

Targeted inhibition of ATP-binding cassette transporter A1 protein degradation promotes reverse cholesterol transport and reduces atherosclerosis in mice (832.15)

Small molecule inducers of ABCA1 and apoE that act through indirect activation of the LXR pathway

Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice

Abstract 506: the Role of Apolipoprotein A-V in Chylomicron Metabolism

Lipid reducing activity of novel cholic acid (CA) analogs: Design, synthesis and preliminary mechanism study.

Native LDL Upregulation of ATP-Binding Cassette Transporter-1 in Human Vascular Endothelial Cells

Abstract 1453: LXR-623, a Novel Liver X Receptor Modulator, Displays Neutral Lipid Effects in Cholesteryl Ester Transfer Protein-expressing Species and Inhibits Atherosclerotic Lesion Progression in Low Density Lipoprotein Receptor Knockout Mice

Inhibition of Soluble Epoxide Hydrolase in Mice Promotes Reverse Cholesterol Transport and Regression of Atherosclerosis

ABCG1--a potential therapeutic target for atherosclerosis.

The Effect of T0901317 on ATP-binding Cassette Transporter A1 and Niemann-Pick Type C1 in Apoe-/- Mice.

Nonlipogenic ABCA1 Inducers (NLAI) for Alzheimer's Disease Validated in a Mouse Model Expressing Human APOE3/APOE4

Abstract 225: Regulation Of Plasma Lipoproteins And Atherosclerosis By Microrna-541-3p And Transcription Factors Znf101 And Casz1

Identification of A Novel Partial Agonist of Liver X Receptor Alpha (lxr Alpha) Via Screening

Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway

Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial

Glucagon-like peptide-1 contributes to increases ABCA1 expression by downregulating miR-758 to regulate cholesterol homeostasis.